Clinical Trials Logo

Obsessive-Compulsive Disorder clinical trials

View clinical trials related to Obsessive-Compulsive Disorder.

Filter by:

NCT ID: NCT06360991 Not yet recruiting - Clinical trials for Obsessive-Compulsive Disorder (OCD)

DBS for Treatment-resistant Obsessive-compulsive Disorder

Start date: April 20, 2024
Phase: N/A
Study type: Interventional

The primary purpose of this study is to investigate the effect of deep brain stimulation (DBS) implantation targeting the anteromedial region of subthalamic nucleus (amSTN), or nucleus accumbens (NAc), or bed nucleus of the stria terminalis (BNST), or ventral capsule/ventral striatum (VC/VS), or the ventral anterior limb of the internal capsule (vALIC) in patients with treatment-resistant obsessive-compulsive disorder (TR-OCD).

NCT ID: NCT06356090 Recruiting - Clinical trials for Obsessive-Compulsive Disorder

SPACE: a Parent-based Treatment for Pediatric OCD

Start date: November 23, 2023
Phase: N/A
Study type: Interventional

This study will investigate the parent-based treatment SPACE: Supportive Parenting for Anxious Childhood Emotions. The aim of this study is to investigate whether SPACE is effective in reducing family accommodation (FA) and OCD symptoms in children with a complex obsessive-compulsive disorder (OCD), that did not or cannot benefit from first line treatment.

NCT ID: NCT06347978 Not yet recruiting - Clinical trials for Obsessive-Compulsive Disorder

Personalized DBS for OCD Guided by Stereoencephalography Mapping

Start date: April 2024
Phase: N/A
Study type: Interventional

This is a double-blinded, randomized, crossover study design for SEEG-guided 4-lead DBS for treatment-refractory OCD, followed by open label stimulation for an additional 6 months. The study will be conducted in 3 stages: Stage 1 will consist of SEEG brain mapping and optimization of stimulation parameters. Stage 2 will consist of 4-lead DBS surgery with bilateral IPGs and further optimization of stimulation parameters. Stage 3 will be randomized, crossover treatment, followed by open label treatment.

NCT ID: NCT06346301 Recruiting - Anxiety Disorders Clinical Trials

Imagery Rescripting as a Stand-alone Treatment for OCD and BDD.

Start date: April 21, 2023
Phase: N/A
Study type: Interventional

The goal of this multiple baseline case series study is to test the effect of imagery rescripting (ImRs) in Obsessive Compulsive Disorder (OCD) and Body Dysmorphic Disorder (BDD). Primary objective :The course of schema or core beliefs and change in OCD and BDD. To investigate the effectiveness of imagery rescripting on factors presumed to underlie the disorder, according to schema theory, and on OCD and BDD symptoms. Secondary objective: The change in OCD and BDD symptoms (full questionnaire), schemata and modes, core emotions, mood, affect and obtrusiveness of intrusion. Other objectives are research into the working mechanisms of imagery rescripting by collecting qualitative data from patients and their practitioner in a qualitative interview. For this study, a multiple-baseline single-case experimental design (SCED) is used testing different outcome variables in 18 OCD patients and 18 BDD patients. After a variable baseline period of 3-8 weeks participants will start twice weekly with imagery rescripting for 12 sessions, followed by a 6 week follow up. Participants will rate schema- or core beliefs and OCD or BDD severity on a visual analogue scale. In addition participants will rate core emotions, affect and obtrusiveness of the intrusion. Secondary we will asses four times questionnaires about OCD of BDD symptoms, depression and schemas en modes. After treatment participants will be interviewed about their experiences.

NCT ID: NCT06339463 Not yet recruiting - Anxiety Disorders Clinical Trials

Self-Distancing for Pediatric Anxiety and OCD

Start date: May 2024
Phase: N/A
Study type: Interventional

Self-Distancing is a cognitive technique that involves shifting perspective away from first person to promote an adaptive, self-reflective stance in emotionally charged situations. This trial aims to help learn how self-distancing may increase approach during exposure and thereby improve treatment response. To find out if self-distancing works by helping children approach fear inducing stimuli, the study will look at behaviors related to approach as well as symptom severity, before, after and during treatment. The study hypothesizes that Self-Distancing will produce greater increases in approach behaviors and greater decreases in anxiety severity than in the Classic Exposure.

NCT ID: NCT06334887 Recruiting - Clinical trials for Obsessive-Compulsive Disorder

esTOCma, an App Used by Teachers: an RCT

Start date: February 26, 2024
Phase: N/A
Study type: Interventional

The aim of the present study is to assess the efficacy of a mobile application called esTOCma in promoting mental health literacy, reducing stigmatizing attitudes related to the Obsessive-Compulsive Disorder (OCD) and improving teachers' confidence in dealing with students that might have OCD. A parallel, randomized controlled trial with two conditions (experimental and control group) will be carried out in a sample of teachers that work in primary and secondary education. Pre-post changes will be assessed. Experimental group will use the app until they finish it (within a set period of 10 days), whereas control group will do nothing for 10 days. Primarily, it is expected that after the use of the app, participants will show an improvement in OCD-related literacy, stigmatizing attitudes, desired social distance and their comfort, confidence and perceived ability in teaching and handling students with OCD. Secondarily, the investigators hypothesize that experimental group might show a reduction in obsessive-compulsive symptoms.

NCT ID: NCT06318806 Not yet recruiting - Clinical trials for Obsessive-Compulsive Disorder

Towards Remission and Full Recovery From Obsessive-compulsive Disorder

RCT2023
Start date: June 1, 2024
Phase: N/A
Study type: Interventional

Obsessive-compulsive disorder (OCD) is a disabling psychiatric illness that is characterized by distressing obsessional thoughts and time-consuming compulsive rituals. Exposure and Response Prevention (ERP) is a first-line psychological treatment of choice that requires patients to face their fears by being exposed to feared stimuli. This treatment has been shown to reduce symptoms in a significant proportion of patients. However, it is considered a difficult treatment and only a minority reach remission. Residual symptoms typically remain, or reappear after treatment, which is a risk for relapse. Inference-based Cognitive Behavioral Therapy (I-CBT) is a promising evidence-based treatment developed to overcome these limitations. I-CBT has already been found to be as effective as ERP and significantly more acceptable and easier to adhere to. There is also evidence that I-CBT is more effective for subgroups of patients. Consequently, the current research project is focused on improving treatments outcomes for those provide those who have previously unable to reach remission of their symptoms with ERP. Following an initial treatment with ERP, those that have been unable to reach remission, will be randomized to either I-CBT or more ERP. It is expected that I-CBT will be significantly more effective than providing patients with more of the same. In addition, the study aims to predict treatment outcome in order to be able to tell in advance which patients do not respond to ERP. The project is designed to maximize beneficial health outcomes with a stepped-care approach to treatment, but also to work towards a more personalized choice by being able to match patients in advance with the treatment that works best for them

NCT ID: NCT06302712 Not yet recruiting - Clinical trials for Obsessive-Compulsive Disorder

Traditional Islamically Integrated Psychotherapy for Muslims With OCD in Pakistan

Start date: April 1, 2024
Phase: N/A
Study type: Interventional

The current study aims to determine the effectiveness of the first culturally adapted Traditional Islamically Integrated Psychotherapy (TIIP) for Muslims with OCD in Pakistan along with the module effectiveness in reducing OCD symptoms with comorbidities like anxiety, depression, stress, thought control, thought-action fusion, and enhancing the spiritual quality of life of participants.

NCT ID: NCT06299319 Not yet recruiting - Clinical trials for Obsessive-Compulsive Disorder

Feasibility, Clinical Effects, and Safety of Psilocybin-assisted Psychotherapy for Treatment-resistant OCD

PAP-OCD
Start date: April 2024
Phase: Phase 1
Study type: Interventional

Psilocybin, the chemical component of "magic mushrooms", has been administered with psychotherapy in several randomized clinical trials (RCTs) showing large and sustained antidepressant effects. There is interest to see if similar effects may be provided in those with obsessive compulsive disorder (OCD). The purpose of this study is to evaluate the safety, feasibility, and clinical effects of psilocybin administration in those with OCD. Ten participants with treatment-resistant OCD will receive two doses of 25mg of psilocybin under supportive conditions, two weeks apart. The investigators hypothesize that two sessions of psilocybin 25mg administered under supportive conditions to participants with treatment-resistant OCD will lead to significant reductions in OCD symptoms.

NCT ID: NCT06265233 Recruiting - Clinical trials for Obsessive-Compulsive Disorder

ERP Plus Improv Group Therapy for OCD (IMPROVE Study)

Start date: February 9, 2024
Phase: N/A
Study type: Interventional

The goal of this study is to pilot test a novel group therapy intervention for adults with OCD.